Osteosarcoma

Osteosarcoma is a primary malignant bone neoplasm defined by the production of osteoid or immature bone by neoplastic mesenchymal cells.[1] It is the most common primary malignancy of the jaws, yet jaw osteosarcoma (JOS) constitutes only 6%–9% of all osteosarcomas and is biologically distinct from its long-bone counterpart, presenting one to two decades later, metastasizing less frequently, and carrying a comparatively better prognosis.[2][3] The mandibular body and the maxillary alveolar ridge are the most common sites.[4][5] Radiographically, JOS is highly variable—radiolucent, radiopaque, or mixed—and commonly produces widening of the periodontal ligament (PDL) space, an important early sign.[6][7] Margin-negative surgical resection is the cornerstone of treatment; the role of adjuvant chemotherapy and radiation remains debated.[3][8]

The 2020 WHO Classification of Tumours of Soft Tissue and Bone classifies osteosarcoma under osteogenic tumours and recognizes conventional (central) osteosarcoma as the most common type, with three major histologic subtypes: osteoblastic, chondroblastic, and fibroblastic.[9] Small-cell and telangiectatic osteosarcoma are now described as variants of conventional osteosarcoma rather than separate entities.[10] Additional recognized subtypes include parosteal (low-grade surface), periosteal (intermediate-grade surface), and high-grade surface osteosarcoma.[11][12] Low-grade central (intramedullary) osteosarcoma is a distinct low-grade entity.[13]

Accepted synonyms include osteogenic sarcoma, the traditional term still encountered in clinical practice.[5][7] The designation gnathic osteosarcoma is used in consensus literature to distinguish mandibular and maxillary tumors from other craniofacial osteosarcomas.[3] The rare epithelioid variant should not be confused with epithelioid morphology in other sarcomas.[14]

• Age: Mean age at diagnosis is approximately 33–41 years, one to two decades older than long-bone osteosarcoma. Maxillary tumors show a peak in the fifth decade; mandibular tumors have a broader age distribution.[1][2]
• Sex: No consistent sex predilection in large population-based data (approximately 1:1). Some smaller series report a slight male predominance.[2][5][15]
• Frequency: JOS accounts for 6%–9% of all osteosarcomas and represents the most common primary malignant bone tumor of the jaws. Among all oral and maxillofacial sarcomas, osteosarcoma is the most frequent subtype.[2][3][16]
• Anatomic distribution: The mandible (body) and maxilla (alveolar ridge) are affected in roughly comparable proportions, with a slight mandibular predominance in most series. All maxillary tumors in one large imaging review originated from the alveolar ridge.[4][5]
• Secondary osteosarcoma: May arise after prior radiation therapy (radiation-associated osteosarcoma) or in the setting of pre-existing Paget disease or fibrous dysplasia. Radiation-associated cases account for a substantial proportion of head and neck osteosarcomas, with a mean latency of approximately 14 years.[4][14][16]

Presenting symptoms

• Swelling is the most common complaint, reported in over 80% of cases. It may be painless initially, particularly in early-stage disease.[5][17][18]
• Pain accompanies swelling in roughly half of patients and may mimic odontogenic pain.[6][17]
• Tooth mobility and loosening occur when the tumor involves the alveolar process and destroys the periodontium.[15][19]
• Paresthesia or dysesthesia of the lip or chin (mental nerve distribution) is an occasional finding in mandibular lesions and should raise suspicion for malignancy.[19][20]

Tempo and diagnostic delay

The average interval between first symptoms and clinical presentation is approximately 3–4 months.[5][17] Early lesions may be misinterpreted as periodontal disease, periapical pathology, or benign fibro-osseous lesions; in one large series, none of the cases received a correct presumptive clinical–radiographic diagnosis of osteosarcoma.[1]

Red flags

Rapid expansion of a jaw mass, unilateral PDL widening on radiographs, unexplained tooth mobility in a young or middle-aged adult, and new-onset paresthesia should prompt urgent further investigation.[18][19]

Osteosarcoma of the jaws is radiographically heterogeneous, and no single feature is pathognomonic. The imaging appearance depends on the degree of tumor osteogenesis, bone destruction, and histologic subtype.[1][7]

Location and distribution

• The mandibular body and the maxillary alveolar ridge are the characteristic sites.[4][5]
• Lesions are typically centered in the medullary bone and extend to involve the alveolar process, cortex, and adjacent soft tissues.[4][20]
• Mandibular lesions may involve the inferior alveolar canal; structural changes of the canal are demonstrable on panoramic radiographs in roughly one-third of mandibular cases.[7]

Periphery and shape

• Borders are diffuse and ill-defined in the majority of cases; defined but non-corticated margins are seen occasionally.[7]
• A well-circumscribed appearance is uncommon and may lead to misdiagnosis as a benign process.[1]
• The transition zone is characteristically long, reflecting aggressive growth.[4]

Internal architecture

• The internal pattern is mixed radiolucent-radiopaque in most cases, reflecting concurrent bone destruction and tumor osteoid production. A purely radiolucent or purely radiopaque pattern each occurs in a minority of cases.[1][7]
• Tumor matrix mineralization is common and may appear as amorphous, cloud-like, or cotton-wool–like opacities within the lesion.[1][21]
• Mandibular osteosarcomas tend to be osteolytic or osteolytic-dominant, whereas maxillary lesions are more often osteogenic or osteogenic-dominant. This site-dependent pattern is clinically important: osteogenic maxillary lesions without obvious bone destruction may closely mimic benign fibro-osseous or cemento-osseous lesions.[4][6]

Effects on teeth and the periodontal ligament

• Widening of the PDL space is a characteristic early sign, best demonstrated on periapical radiographs. It is typically unilateral and involves teeth at the periphery of the tumor.[6][7][18]
• Tooth displacement and abnormal mobility are common as the tumor infiltrates the alveolar bone.[15][18]
• Root resorption occurs but is less prominent than in some other aggressive jaw lesions.[15]
• Calcification above the alveolar crest (supracrestal mineralization) is an important finding that may simulate exuberant crestal bone growth.[15][18]

Cortical involvement and periosteal reaction

• Cortical destruction of the buccal, lingual/palatal, or basal plate is common, observed in approximately three-quarters of cases with available imaging.[1]
• Periosteal reaction is present in roughly half of cases on conventional radiographs and is best demonstrated on occlusal views. Patterns include:[7]
  • Sunburst (divergent spiculated): Radiating spicules of mineralized tumor matrix perpendicular to the cortical surface; characteristic of osteosarcoma but seen in only a minority of jaw cases.[1][6][22]
  • Codman triangle: Elevated, disrupted periosteum at the tumor margin; occasional.[6][22]
  • Hair-on-end (parallel spiculated): Less commonly described in the jaws.[22]
• The sunburst pattern, while often considered suggestive of osteosarcoma, is neither frequent nor entirely specific.[1]

Soft-tissue extension

• Extraosseous tumor extension is common at presentation and may contain calcifications.[4]
• Cross-sectional imaging (CBCT or medical CT) is superior to panoramic radiography for detecting cortical perforation, soft-tissue involvement, and the full extent of the lesion.[4][23][24]

Recognized variants

• Periosteal osteosarcoma of the jaws is rare and presents as a surface-based mass without marrow involvement, potentially mimicking a gingival or peripheral lesion.[25]
• Telangiectatic osteosarcoma may appear as a purely lytic, expansile lesion.[11][21]

Medical CT

CT excels at detecting tumor matrix mineralization (present in over 75% of cases), cortical destruction, and calcifications within the soft-tissue component.[4][26] Lytic density is the most common CT pattern in head and neck osteosarcoma, followed by mixed and sclerotic patterns.[26] Spiculated periosteal reactions are identified on CT in the majority of cases where periosteal reaction is present.[26]

MRI

MRI is the preferred modality for staging, providing superior delineation of intramedullary extent, soft-tissue invasion, and neurovascular involvement.[4][13][27] Tumors typically show low-to-heterogeneous signal on T1-weighted images and heterogeneous signal on T2-weighted images, with variable enhancement patterns that may correlate with histologic subtype (e.g., peripheral enhancement in chondroblastic tumors).[26] MRI is less sensitive than CT for detecting matrix mineralization and cortical bone destruction.[4]

FDG-PET/CT and bone scintigraphy

NCCN guidelines recommend FDG-PET/CT (head-to-toe) and/or bone scan as part of the staging workup to evaluate for distant metastases and skip lesions.[13]

The radiographic heterogeneity of jaw osteosarcoma creates overlap with both benign and malignant entities. The mixed or osteogenic pattern may mimic fibro-osseous lesions, while the osteolytic pattern overlaps with other aggressive jaw pathology. Unilateral PDL widening, rapid clinical progression, and aggressive periosteal reaction are the most useful discriminators favoring osteosarcoma.

The highest-risk diagnostic pitfall is misidentifying an osteogenic maxillary osteosarcoma as a benign cemento-osseous or fibro-osseous lesion, since these may appear radiographically similar and none of the cases in one large series received a correct presumptive diagnosis.[1] Incisional biopsy with adequate tissue is essential; small or superficial samples may be non-diagnostic, particularly in high-grade tumors with scant osteoid.[14]

Diagnostic criteria

The defining histologic feature is the production of neoplastic osteoid or bone by malignant mesenchymal cells.[1][12] Osteoid appears as lace-like eosinophilic networks between individual tumor cells and may undergo focal calcification.[14][31] Microscopic examination remains the gold standard and should be performed in conjunction with radiologic review.[13]

Histologic subtypes

The three major subtypes—osteoblastic, chondroblastic, and fibroblastic—are defined by the predominant extracellular matrix.[12][15] The relative frequency of subtypes in the jaws is debated:

• Chondroblastic is the most common subtype in several combined series, characterized by lobules of atypical cartilage with peripheral osteoid formation.[5][15]
• Osteoblastic predominates in other large series, with osteoid production by atypical polygonal cells.[1]
• Fibroblastic is the least common, showing focal osteoid amid atypical spindle cells.[15]
• More than one differentiation pattern may coexist within a single tumor.[1]

Rare variants

The epithelioid variant is rare and may be misdiagnosed as poorly differentiated carcinoma on small biopsy specimens.[14] Giant cell–rich, small-cell, and telangiectatic patterns are occasionally encountered.[1][11]

Grading and radiologic-pathologic correlation

Approximately equal proportions of low-grade and high-grade tumors are reported in some jaw series, in contrast to long-bone osteosarcoma where over 90% are high grade.[1][12] Low-grade jaw osteosarcoma can be difficult to distinguish from benign fibro-osseous lesions histologically; correlation with imaging and clinical behavior is critical.[1][32]

Molecular findings

Osteosarcoma is characterized by complex, often chaotic karyotypes with frequent alterations in TP53 (most common), RB1, and CDKN2A/B.[33] MDM2 amplification has been identified in a subset of mandibular osteosarcomas, including differentiated/dedifferentiated variants and a novel ossifying fibroma–like subtype with RASAL1/MDM2 co-amplification.[32] FOS rearrangement, characteristic of osteoid osteoma and osteoblastoma, can serve as an ancillary test to distinguish these benign entities from osteosarcoma.[10]

Workup and referral

Any jaw lesion with clinical or radiographic features suspicious for osteosarcoma warrants urgent referral to a multidisciplinary sarcoma team.[3][13] NCCN guidelines recommend contrast-enhanced MRI ± CT of the primary site, chest CT, FDG-PET/CT and/or bone scan, serum LDH and alkaline phosphatase, and fertility consultation.[13] Biopsy should be performed by or in coordination with the treating surgical team, and pathologic evaluation should be conducted by an experienced sarcoma pathologist.[13]

Definitive treatment

• Surgery: Margin-negative (R0) wide surgical resection is the single most important prognostic factor and the primary treatment modality. Achieving clear margins in the jaws is more challenging than in the extremities due to complex anatomy. Positive margins are significantly associated with worse overall survival, disease-free survival, and increased local recurrence.[2][3][8][34][35]
• Chemotherapy: The role of chemotherapy in JOS remains controversial. A recent meta-analysis demonstrated a significant survival benefit for chemotherapy combined with surgery in high-grade JOS (HR 0.50). A large multicenter mandibular series found that neoadjuvant chemotherapy improved disease-free and metastasis-free survival and increased clear-margin rates. However, consensus recommendations note that the benefit of neoadjuvant chemotherapy is less established than in long-bone osteosarcoma, and direct radical surgery may be preferred when R0 resection is achievable. NCCN-preferred first-line regimens include cisplatin/doxorubicin and MAP (high-dose methotrexate, doxorubicin, cisplatin).[3][8][13][35][36]
• Radiation therapy: Osteosarcoma is not highly radiosensitive. Radiation is reserved for positive margins (55 Gy + boost to 64–68 Gy) or unresectable disease (60–70 Gy). Proton or carbon-ion therapy may be advantageous for craniofacial tumors to spare adjacent critical structures.[13][37]

Prognosis

• Five-year overall survival ranges from approximately 53%–77% depending on the series and treatment approach.[2][8][38]
• Favorable prognostic factors: Younger age, mandibular location, negative surgical margins, smaller tumor size, and primary (non-radiation-associated) tumors.[8][34][39]
• Local recurrence is the predominant mode of failure in JOS, occurring in up to 42% of cases, in contrast to long-bone osteosarcoma where distant metastasis predominates. Distant metastasis rates are substantially lower than in extremity osteosarcoma.[2][5][17][39]

Surveillance

Long-term follow-up with serial imaging is essential given the high local recurrence rate. NCCN surveillance protocols for osteosarcoma include periodic physical examination, imaging of the primary site, and chest imaging.[13]

Radiation-associated osteosarcoma

Secondary osteosarcoma arising after radiation therapy for prior head and neck malignancy (most commonly nasopharyngeal carcinoma) accounts for a substantial proportion of jaw osteosarcomas in some series.[4][14][16] The latency period ranges from approximately 4 to 50 years (mean ~14 years), and these tumors tend to arise at the borders of the prior